Q3 REPORT

April – June 2026











CSMEDICA

WORLD-CHANGING PRODUCTS FOR A BETTER EVERY DAY

BRIEFLY ABOUT CS MEDICA A/S

CS MEDICA is a Danish MedTech company combining research, technology and nature to advance human health. We develop IPR-secured, MDR-certified medical devices designed to improve quality of life by redefining how pain, autoimmune conditions and stress-related disorders are treated – including arthritis, psoriasis, insomnia, allergies, hair loss and other chronic discomforts.

Our purpose is rooted in the scientific understanding of the endocannabinoid system, the documented therapeutic properties of the cannabis plant and long-standing pharmaceutical expertise. This foundation enables us to create non-addictive, CE-marked and clinically documented alternatives that deliver effective relief with a favourable tolerability profile.

Our portfolio consists of CE-marked products and an expanding pipeline of evidence-based formulations, protected by patents and trademarks across key global markets. The products – topical creams, gels, lotions, sprays and patches – are registered internationally as over-the-counter (OTC) medical devices and are commercialised through own brands and white-label partnerships in more than 35 countries, with further potential through out-licensing.

Built on a capital-light, ISO-certified outsourced manufacturing model and strict compliance with ISO 13485, ISO 14971, ISO 10993, EU MDR, UK MDR and FDA requirements, CS MEDICA offers scalable, high-quality production and a robust supply chain. This regulatory platform represents a significant barrier to entry and a strong foundation for international growth and partnerships.

Across both human and veterinary applications, we harness the power of nature to create treatments that combine proven efficacy with improved tolerability – enabling better everyday living for patients, whether on two legs or four.

35+ countries

First mover combining CBD and OTC

CE-marked topical creams, gels & spray

1 million units shipped

4 patents + 7 patent pending

9 products launched

Clinical trials & studies

13+ products in pipeline



COMMENTS FROM MANAGEMENT

Q3: Improved Operating Performance
The third quarter of 2025/2026 showed a clear improvement in the Group's operating performance. Net sales reached **DKK 2.86 million** and gross profit **DKK 1.71 million**, corresponding to a gross margin of approximately **60%**. The operating loss narrowed to **DKK 0.36 million** from DKK 1.61 million in Q3 2024/2025. The net loss was **DKK 0.81 million** (DKK 1.98 million).

For the first nine months, net sales increased to **DKK 6.89 million** (DKK 1.57 million), while the operating loss was reduced to **DKK 4.52 million** (DKK 7.71 million) and the net loss to **DKK 4.49 million** (DKK 7.92 million).

The improvement reflects stronger commercial activity, including a significant white-label delivery to an established European partner, combined with the cost consolidation undertaken across the organisation. The next step is to convert this progress into recurring revenue and positive operating cash flow.

Commercial Execution and Production
Previously delayed activities have progressed into production, delivery and invoicing. Management's focus is now on execution – production planning, CMO management, shorter lead times and gross-margin protection. As individual customer orders are material relative to the Group's current scale, revenue may vary between quarters.

Regulatory and IP
Pain Patch and Psoriasis Gel provide an established MDR foundation, and work continues on the remaining Class IIa portfolio and market-specific registrations. MDR certification and a strong patent portfolio are key competitive advantages, but they also require significant investment in Notified Body (BSI) fees and patent costs. Management is therefore prioritising regulatory and IP spending towards the products and markets with the greatest commercial potential.

Liquidity and Funding
The improved operating result has not yet translated into positive cash flow. Cash flow from operating activities was negative at **DKK 3.20 million** in Q3 and DKK 11.16 million year-to-date, mainly reflecting the reduction of trade and other payables. At **30 June 2026**, cash and cash equivalents amounted to **DKK 0.38 million** and Group equity was negative at **DKK 8.07 million**. Additional working-capital financing has been secured and partly received during and after the quarter, and liquidity remains a key priority.

Corporate and Capital Structure
The Board and Management are working on a restructuring of the Group's corporate and capital structure to create a simpler and stronger platform for the CS MEDICA/ CANNORDIC business. The aim is to strengthen the capital base, reduce complexity and align the financing structure with the operating business.

Outlook
Management's priorities are to convert confirmed orders and the commercial pipeline into invoicing and cash, complete the restructuring, progress the MDR portfolio and increase repeat orders to improve predictability. The next milestone is sustainable EBITDA and cash-positive operations, creating a stronger foundation for long-term growth.

On behalf of the Board of Directors and Executive Management
CS MEDICA A/S

KEY FIGURES

	Quarter 3		YTD	
	2025/2026 DKK	2024/2025 DKK	2025/2026 DKK	2024/2025 DKK
Net sales	2.862.034	- 38.898	6.890.598	1.569.726
Gross profit	1.708.052	559.590	3.512.126	1.015.318
Operating profit	- 363.492	- 1.611.214	- 4.521.274	- 7.714.954
Depreciation and amoritsation	- 475.729	- 416.517	- 1.415.121	- 1.601.634
Net financials	- 699.394	- 762.920	- 1.534.412	- 2.343.250
Profit before taxes	- 1.062.886	- 2.374.133	- 6.055.686	- 10.058.204
Net profit	- 807.051	- 1.977.740	- 4.486.045	- 7.923.346
Credit bank /Cash and cash equivalents	378.342	- 155.074	378.342	- 155.074
Addition R&D costs	307.160	245.241	732.975	2.311.451
Cash flow	376.027	78.726	487.562	640.297
Total Assets	30.185.973	36.904.678	30.185.973	36.904.678
Equity	- 8.074.833	561.749	- 8.074.833	561.749
Financial Ratios				
Gross margin	60%	-1439%	51%	65%
Operating margin	-13%	4142%	-66%	-491%
Addition R&D cost in % of sale	11%	-630%	11%	147%
Net profit margin	-28%	5084%	-65%	-505%
Equity ratio	-27%	2%	-27%	2%

COMPANY INFORMATION

CS MEDICA A/S
CVR: 33871643
Founding date: 17.08.2011
Research startup: 2015
First products launched: 2021

Headquarters: Copenhagen

Financial period: 1 October – 30 September

Executive Management

- Lone Henriksen
- Gitte Henriksen
- Mikkel Raahauge Nielsen

Financial Calendar

Follow updates on the cs-medica.com website.

Financial Statements

Income Statement

1 April – 30 June 2026

	Quarter 3		Yeart-To-Date	
	2025/2026 DKK	**2024/2025** DKK	**2025/2026** DKK	**2024/2025** DKK
Income Statement				
Net Sales	2.862.034	-38.898	6.890.598	1.569.726
Costs of goods sold	-1.153.982	598.488	-3.378.472	-554.408
Gross Profit	**1.708.052**	**559.590**	**3.512.126**	**1.015.318**
Other operating income	0	0	0	77.500
Sales and distribution cost	-357.156	142.487	-1.214.136	-251.997
Administrative costs	-526.261	-237.765	-1.474.715	-1.868.068
Staff costs	-712.398	-1.659.009	-3.929.431	-5.086.076
Depreciation and amoritsation	-475.729	-416.517	-1.415.121	-1.601.634
Operating profit	**-363.492**	**-1.611.214**	**-4.521.277**	**-7.714.957**
Income from equity investments in group enterprises	0	0	0	0
Financial costs net	-699.394	-762.920	-1.534.409	-2.343.247
Profit or loss before tax	**-1.062.886**	**-2.374.133**	**-6.055.686**	**-10.058.204**
Tax on net profit or loss for the year	255.835	396.394	1.569.641	2.134.858
Net profit or loss for the year	**-807.051**	**-1.977.740**	**-4.486.045**	**-7.923.346**
Comprehensive income				
Net profit or loss for the year	-807.051	-1.977.740	-4.486.045	-7.923.346
Other comprehensive income:				
Cost Diret Issue & IPO	0	0	0	0
Total comprehensive income for the year	**-807.051**	**-1.977.740**	**-4.486.045**	**-7.923.346**

Balance
30 June 2026

	30. June 2026	30. June 2025
	DKK	DKK
Balance Sheet		
Assets		
Development projects & IPR rights	13.283.302	13.298.009
Rights	1.918.508	2.277.532
Equity investments in Joint Venture enterprises	0	4.113.010
Deferred tax assets	13.379.085	14.413.590
Deposits	155.991	0
Total non-current assets	**28.736.886**	**34.102.141**
Work in progress	0	0
Manufactured goods and goods for resale	424.983	1.737.242
Trade receivables	246.275	816.738
Other receivables	399.487	395.945
Cash and equivalents	378.342	-155.074
Total current assets	**1.449.087**	**2.802.537**
Total assets	**30.185.973**	**36.904.678**

Balance
30 June 2026

	30. June 2026	30. June 2025
	DKK	DKK
Equity and liabilities		
Share Capital	1.236.732	1.236.732
Reserve for net revaluation according to the equity method	0	0
Reserve for development costs	10.360.975	10.372.446
Retained earnings	-19.672.540	-11.047.431
Other Capital reserves	0	0
Total equity	**-8.074.833**	**561.748**
Other privisions	0	4.802.000
Subordinate loan capital	13.032.851	10.176.699
Interest bearing liabilities	0	562.937
Total non-current liabilities	**13.032.851**	**15.541.636**
Prepayments received from customers	1.672.258	4.699.094
Credit bank	0	0
Interest bearing liabilities	16.822.295	4.636.828
Trade payables	4.916.637	8.278.612
Other payables	1.816.764	3.186.759
Total current liabilities	**25.227.954**	**20.801.294**
Total liabilities	**30.185.973**	**36.904.678**

Equity Statement

1 April – 30 June 2026

	Quarter 3		Yeart-To-Date	
	2025/2026	**2024/2025**	**2025/2026**	**2024/2025**
	DKK	DKK	DKK	DKK
Balance, beginning of period	1.236.732	1.113.179	1.236.732	1.113.179
Change	0	123.554	0	123.554
Contributed capital, end of period	**1.236.732**	**1.236.732**	**1.236.732**	**1.236.732**
Balance, beginning of period	0	0	0	0
Change	0	0	0	0
Reserve for net revaluation, end of period	**0**	**0**	**0**	**0**
Balance, beginning of period	10.395.258	10.546.116	10.613.011	7.116.933
Change	-34.283	-173.668	-252.035	3.255.514
Reserve for development costs,end of period	**10.360.975**	**10.372.447**	**10.360.975**	**10.372.447**
Balance, beginning of period	-19.588.761	-11.626.297	-16.127.521	-2.214.159
Share premium	0	2.382.938	0	2.382.938
Deferred tax	0	0	0	0
IPO cost and capital raising	0	0	0	-37.350
Reserve for development costs	34.283	173.667	252.035	-3.255.516
Retained earnings for the period	-118.061	-1.977.740	-3.797.055	-7.923.346
Retained earnings,end of period	**-19.672.540**	**-11.047.432**	**-19.672.540**	**-11.047.432**
Total Equity, end of period	**-8.074.833**	**561.748**	**-8.074.833**	**561.748**

Cash flow and capital allocation

1 April – 30 June 2026

	Quarter 3		Yeart-To-Date	
	2025/2026	2024/2025	2025/2026	2024/2025
	DKK	DKK	DKK	DKK
Cash Flow statement				
Profit/loss before tax	-807.051	-1.977.740	-4.486.042	-7.923.343
Financial expenses, reversed	699.394	762.920	1.534.409	2.343.247
Depreciation, reversed	475.729	416.517	1.415.121	1.601.634
Changes in working capital	-3.565.412	898.803	-9.622.789	3.835.976
Cash flows from operating activities	**-3.197.340**	**100.500**	**-11.159.300**	**-142.486**
Investing in Developnment projects	-307.160	-245.241	-732.975	-2.311.451
Cash flow from investment activities	**-307.160**	**-245.241**	**-732.975**	**-2.311.451**
Share capital	0	123.554	0	123.554
Share premium	0	2.382.938	0	2.382.938
Financial expenses paid	-699.394	-762.920	-1.534.412	-2.343.250
IPO cost and capital raising	0	0	0	-37.350
Loan internal partners	2.511.898	497.983	2.685.837	2.053.027
Credit institutions	0	0	-508.268	25.487
Loan - short	2.068.023	-2.018.089	11.736.681	889.828
Cash flow from financing activities	**3.880.527**	**223.466**	**12.379.837**	**3.094.234**
Total cashflows end of period	**376.027**	**78.726**	**487.562**	**640.297**
Cash/Credit, beginning of period	2.315	-233.800	-109.220	-795.371
Cash/ Credit , end of period	**378.342**	**-155.074**	**378.342**	**-155.074**

	Quarter 3		Yeart-To-Date	
	2025/2026	2024/2025	2025/2026	2024/2025
	DKK	DKK	DKK	DKK
Change in working capital				
Change in Finished goods	402.292	-763.649	1.064.461	-773.997
Trade + other receivables	672.174	1.086.736	-740.304	2.902.320
Trade + other payables	-4.384.043	922.796	-9.191.731	3.793.198
Other provisions	0	0	0	0
Deferred tax	-255.835	-396.394	-651.220	-2.134.858
Joint Venture, not consolidated	0	-7.687	0	-7.687
Deposits	0	57.000	-103.994	57.000
	-3.565.412	**898.803**	**-9.622.789**	**3.835.976**

Financial Statements – Parent Company

Income Statement

1 April – 30 June 2026

	Quarter 3		Year-To-Date	
	2025/2026 DKK	**2024/2025** DKK	**2025/2026** DKK	**2024/2025** DKK
Net Sales	0	5.861	181.464	820.884
Gross Profit	**0**	**5.861**	**181.464**	**820.884**
Sales and distribution cost	5.780	0	-14.946	-16.423
Administrative costs	23.801	-114.658	-260.988	-859.093
Staff costs	237.668	-492.071	-663.143	-2.729.693
Depreciation and amoritsation	-206.505	-127.289	-610.897	-230.440
Operating profit	**60.744**	**-728.157**	**-1.368.510**	**-3.014.765**
Income from equity investments in group enterprises	-116.987	-845.695	-2.320.534	-4.136.942
Financial costs net	-618.029	-562.712	-1.590.032	-1.891.479
Profit or loss before tax	**-674.271**	**-2.136.565**	**-5.279.076**	**-9.043.185**
Tax on net profit or loss for the year	144.603	158.825	890.598	1.119.840
Net profit or loss for the year	**-529.669**	**-1.977.740**	**-4.388.478**	**-7.923.346**
Comprehensive income				
Profit or loss before tax	-529.669	-1.977.740	-4.388.478	-7.923.346
Other comprehensive income:				
Cost Diret Issue & IPO	0	0	0	0
Total comprehensive income for the year	**-529.669**	**-1.977.740**	**-4.388.478**	**-7.923.346**

Balance
30 June 2026

	30. June 2026 DKK	30. June 2025 DKK
Balance Sheet		
Assets		
Development projects & IPR rights	4.064.076	3.701.757
Equity investments in associated & group enterprises	3.896.942	13.502.293
Deferred tax assets	5.588.386	6.527.942
Deposits	0	0
Total non-current assets	**13.549.405**	**23.731.992**
Receivables from group enterprises	8.662.111	-147.853
Other receivables	397.880	410.380
Cash and equivalents	-123	-148.290
Total current assets	**9.059.868**	**114.237**
Total assets	**22.609.273**	**23.846.229**

	30. June 2026 DKK	30. June 2025 DKK
Equity and liabilities		
Share Capital	1.236.732	1.236.732
Reserve for net revaluation according to the equity method	0	0
Reserve for development costs	3.169.980	2.887.371
Retained earnings	-12.174.403	-3.562.354
Total equity	**-7.767.691**	**561.749**
Provissions for deferred tax	0	0
Other privisions	0	4.802.000
Subordinate loan capital	11.739.635	9.021.028
Interest bearing liabilities	0	0
Total non-current liabilities	**11.739.635**	**13.823.028**
Interest bearing liabilities	16.322.295	4.636.828
Credit bank	0	0
Trade payables	2.107.858	3.176.180
Other payables	207.176	1.648.445
Total current liabilities	**18.637.329**	**9.461.452**
Total liabilities	**22.609.273**	**23.846.229**

Equity Statement

1 April – 30 June 2026

	Quarter 3		Year-To-Date	
	2025/2026	**2024/2025**	**2025/2026**	**2024/2025**
	DKK	DKK	DKK	DKK
Balance, beginning of period	1.236.732	1.113.179	1.236.732	1.113.179
Change	0	123.554	0	123.554
Contributed capital, end of period	**1.236.732**	**1.236.732**	**1.236.732**	**1.236.732**
Balance, beginning of period	0	0	0	0
Change	0	0	0	0
Reserve for net revaluation, end of period	**0**	**0**	**0**	**0**
Balance, beginning of period	3.094.511	2.909.299	2.997.492	2.328.472
Change	75.469	-21.928	172.488	558.899
Reserve for development costs,end of period	**3.169.980**	**2.887.371**	**3.169.980**	**2.887.371**
Balance, beginning of period	-12.258.255	-3.989.481	-8.302.427	2.574.302
Share premium	0	2.382.938	0	2.382.938
Reserve for net revaluation according to the equity method	0	0	0	0
subsidiaries	0	0	0	0
IPO cost and capital raising	0	0	0	-37.350
Reserve for development costs	-75.469	21.928	516.502	-558.899
Retained earnings for the period	159.321	-1.977.740	-4.388.478	-7.923.346
Retained earnings,end of period	**-12.174.403**	**-3.562.354**	**-12.174.403**	**-3.562.354**
Total Equity, end of period	**-7.767.691**	**561.749**	**-7.767.691**	**561.749**

Cash flow and capital allocation

1 April – 30 June 2026

	Quarter 3		Year-To-Date	
	2025/2026	**2024/2025**	**2025/2026**	**2024/2025**
	DKK	**DKK**	**DKK**	**DKK**
Cash Flow statement				
Profit/loss before tax	-529.669	-1.977.740	-4.388.478	-7.923.346
Financial expenses, reversed	618.029	562.712	1.590.032	1.891.479
Depreciation, reversed	206.505	127.289	610.897	708.738
Changes in working capital	-3.609.406	1.278.034	-4.700.358	4.570.092
Cash flows from operating activities	**-3.314.541**	**-9.704**	**-6.887.907**	**-753.037**
Investing in Developnment projects	-183.585	-150.552	-473.012	-946.576
Cash flow from investment activities	**-183.585**	**-150.552**	**-473.012**	**-946.576**
Share capital	0	123.554	0	123.554
Share premium	0	2.382.938	0	2.382.938
Financial expenses paid	-618.029	-562.712	-1.590.032	-1.891.479
IPO cost and capital raising	0	0	0	-37.350
Loan internal partners	2.549.698	402.312	2.623.887	897.355
Credit institutions	0	0	0	-6.121
Loan - short	1.568.023	-2.018.089	6.434.681	889.828
Cash flow from financing activities	**3.499.692**	**328.002**	**7.468.536**	**2.358.726**
Total cashflows end of period	**1.566**	**167.746**	**107.616**	**659.113**
Cash/Credit, beginning of period	-1.688	-316.037	-107.739	-807.403
Cash/ Credit , end of period	**-123**	**-148.290**	**-123**	**-148.290**

	Quarter 3		Year-To-Date	
	2025/2026	**2024/2025**	**2025/2026**	**2024/2025**
	DKK	DKK	DKK	DKK
Change in working capital				
Trade + other receivables	0	86.770	12.500	-172.180
Trade + other payables	-2.168.479	-784.369	-3.575.778	294.138
Other provisions	0	-92.638	0	0
Deferred tax	-144.603	-158.825	27.823	-1.119.840
Loan Group Enterprises	-1.296.324	2.170.095	-1.164.904	5.510.973
Deposits	0	57.000	0	57.000
	-3.609.406	**1.278.034**	**-4.700.358**	**4.570.092**

	30. June 2026 DKK	30. June 2025 DKK
Equity investments in associated & group enterprises		
Equity Subsidaries		
CANNORDIC A/S (100%)	1.978.434	-7.085.561
Galaxa Pharma A/S (100%)	0	-26.190
	1.978.434	
Equity Joint Venture		
Capital RongShi MEDICA Ltd (49%)	0	11.224.761
Rights	1.918.508	2.277.532
Equity end of period	**3.896.942**	**13.502.293**

Difference between Group and Parent Company

The difference between the Group's and the Parent Company's net result and equity relates to Galaxa Pharma ApS. As Galaxa Pharma ApS has negative equity, the investment is measured at DKK 0 in the Parent Company, and its negative equity and results are not recognised. At 30 June 2026, the difference amounted to DKK 0.31 million in equity and DKK 0.10 million in net result for the first nine months.